Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio
Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

 Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

 Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

 Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025